Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Crohn’s Disease Treatment Market – Global Insights
Crohn’s disease is a form of inflammatory bowel disease (IBD) that refers to a chronic inflammatory condition of the gastrointestinal tract causing inflammation in the digestive tract. The disease is confined to the colon of the large intestine and ileum of the small intestine. The disease if often painful and debilitating and can lead to life-threatening complications in some cases. These complications may comprise of one or more factors that includes bowel obstruction, fistulas, ulcers, anal fissures, colon cancer, and other health issues. Crohn’s disease can be caused due to factors such as stress, diet, heredity and malfunctioning of the immune system. The disease can occur at any age, however is likely to develop at young ages among majority of the individuals. There are no specific and dedicated tests to diagnose the Crohn’s disease and is confirmed after ruling out the possible symptoms and signs of the disease.
There exists no specific cure for the disease, however various therapies can be employed on patients that can help to reduce signs and symptoms of the disease as well as can also bring long-term remission. Improvement in long-term prognosis can be achieved through several medications prescribed for the treatment of Crohn’s disease that include anti-inflammatory drugs, immune system suppressers, antibiotics and other medication that helps to control inflammation.
The global Crohn’s disease treatment market was valued at US$ 9.4 billion in 2017 and is expected to witness a CAGR of 4.3% over the forecast period (2017–2025).
Figure 1. Global Crohn’s Disease Treatment Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights (2018)
Factors such as increasing number of gastrointestinal diseases as well as rising number of patients suffering from Crohn’s disease is expected to significantly contribute to growth of the Crohn’s disease treatment market. According to the Lancet 2016, the global burden of inflammatory bowel disease contributes to 0.3% of the total disease burden of the globe. According to the National Institute of Health, Crohn’s disease and ulcerative colitis affected 1.5 million people in North America and 2.5 million people in the Europe in 2015.
Moreover, development of new and effective therapy options to cure the symptoms of the disease is also a vital factor contributing to the growth of Crohn’s disease treatment market. For instance, researchers from University of Washington Medicine at the Crohn's & Colitis Congress held in January 2018 presented a study that developed an antibiotic that showed four fold better response on the inflammation of intestine among patients suffering with Crohn’s disease as compared to the existing therapies available in the market.
Additionally, increasing government initiatives for improving health care infrastructure is responsible for the market growth. For instance, The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) is an umbrella organization that represents 34 national patient associations and works for improving the life of patients suffering with irritable bowel syndrome in various countries across Europe.
However, low awareness about the available treatment options among the people of middle and low-income economies as well as biologics going off-patent are expected to hinder the market growth.
In terms of market size, North America dominates the global Crohn’s disease treatment market. This is attributed to rapid development and launch of novel biosimilars and drugs for the treatment of disease by the key players in the market in the region. For instance, in August 2016, the U.S. Food and Drug Administration (FDA) approved two biosimilars Erelzi and Amjevita, manufactured by Amgen for the treatment of inflammatory bowel disease. Moreover, a large population pool of patients suffering from Crohn’s disease in Canada is expected to further support the growth of region in the global market. For instance, according to the Candian Society of Intestinal Research 2011, Canada had the highest incidence of Crohn’s disease reported across the world with over 13.4 new cases per 100,000 of population. On the other hand, Asia Pacific is expected to exhibit high growth over the forecast period, owing to regional manufacturers developing biosimilars and generic versions of drugs for the treatment of Crohn’s disease. For instance, in April 2016, the U.S. Food and Drug Administration (FDA) approved Inflectra developed by Celtrion, Inc. a Korean company, which is a biosimilar to Remicade patented by Janssen Biotech, Inc. for adult and pediatric patients suffering with Crohn’s disease and have inadequate response to conventional therapies.
Market players are engaged in innovative product launches to sustain their position in the global Crohn’s disease treatment market
Key players in the market are focused on expansion of their presence through launch of new drugs and treatment options worldwide. For instance, in September 2016, Janssen Biotech, Inc, received FDA approval for STELARA for the treatment of moderate to severe Crohn’s disease that have failed responding to the immunomodulators and corticosteroid treatments earlier. Moreover, application of fast-track approval programs by FDA pertaining to IBD treatments is also expected to provide opportunities to market players to capitalize upon and improve significance in the global Crohn’s disease market. The Center for Drug Evaluation and U.S. FDA released a new document named New Drug Therapy Approvals in 2017 that included fast-track drug and biosimilar approval clauses for Crohn’s disease and inflammatory bowel disease.
Key players operating the global Crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Allergan Inc., Bayer AG, Bristol-Myers Squibb, Pfizer, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.